SPIA
DNLI icon

Steward Partners Investment Advisory’s Denali Therapeutics DNLI Stock Holding History

Steward Partners Investment Advisory’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.74K Buy
340
+204
+150% +$4.19K ﹤0.01% 3784
2026
Q1 		$2.61K Buy
+136
New +$2.71K ﹤0.01% 3975
2025
Q2 		– Sell
-25
Closed -$340 – 4155
2025
Q1 		$340 Hold
25
– – ﹤0.01% 3890
2024
Q4 		$510 Buy
+25
New +$640 ﹤0.01% 3847

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steward Partners Investment Advisory's DNLI Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its Denali Therapeutics (DNLI) stake by 150% in Q2 2026, buying an estimated $4.19K and bringing the position to 340 shares worth $8.74K. The position accounts for ﹤0.01% of the portfolio, ranked #3784.

Steward Partners Investment Advisory first reported a position in DNLI in Q4 2024 and has held it in 4 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Steward Partners Investment Advisory held 340 shares of Denali Therapeutics worth $8.74K as of Q2 2026.
  • Steward Partners Investment Advisory bought 204 Denali Therapeutics shares in Q2 2026, an estimated $4.19K.
  • Denali Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3784 holding.
  • Steward Partners Investment Advisory first reported a position in Denali Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.